Home » Authors » Cormac Sheridan

Articles by Cormac Sheridan

EU Gives EUR9.7M To Consortium For Research Into NCAM Drugs

June 23, 2004

By Cormac Sheridan

Active Biotech, Teva In Potential $92M Deal For Oral MS Product

June 16, 2004

By Cormac Sheridan

Active Biotech, Teva In Potential $92M Deal For Oral MS Product

June 16, 2004

By Cormac Sheridan

Active Biotech, Teva In Potential $92M Deal For Oral MS Product

June 16, 2004

By Cormac Sheridan

Active Biotech, Teva In Potential $92M Deal For Oral MS Product

June 16, 2004

By Cormac Sheridan

IQ Corp., U.S. Navy Enter Deal To Develop Biodefense Agents

June 9, 2004

By Cormac Sheridan

IQ Corp., U.S. Navy Enter Deal To Develop Biodefense Agents

June 9, 2004

By Cormac Sheridan

Cellectricon, InDex Raise Cash To Fund Short-Term Objectives

June 2, 2004

By Cormac Sheridan

Cellectricon, InDex Raise Cash To Fund Short-Term Objectives

June 2, 2004

By Cormac Sheridan

Basilea Becomes Sole Owner Of BAL5788; Roche Opts Out

May 26, 2004

By Cormac Sheridan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...